Invasive Carcinoma — Trials

Invasive Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,812 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 603
Recruiting: 301
Ph III recruiting: 36
Growth YoY: +27.2%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (282)

clinicaltrialsPublishedShowing 151–157 of 157 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03907527	Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	active not recruiting	Phase 1	71	Precigen, IncINDUSTRY	1	Nov 8, 2024	clinicaltrials
NCT05403554	A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers	recruiting	Phase 1	70	Light Chain Bioscience - Novimmune SAINDUSTRY	2	Oct 29, 2024	clinicaltrials